ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for pro Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.

CRSP CRISPR Therapeutics AG

53.92
-0.14 (-0.26%)
May 31 2024 - Closed
Delayed by 15 minutes

Period:

Draw Mode:

Volume 1,119,169
Bid Price 53.40
Ask Price 54.25
News (3)
Day High 54.735

Low
37.55

52 Week Range

High
91.10

Day Low 53.38
Share Name Share Symbol Market Stock Type
CRISPR Therapeutics AG CRSP NASDAQ Common Stock
  Price Change Price Change % Share Price Last Trade
-0.14 -0.26% 53.92 19:00:00
Open Price Low Price High Price Close Price Previous Close
54.26 53.38 54.735 53.74 54.06
Trades Shares Traded VWAP Financial Volume Average Volume 52 Week Range
18,766 1,119,169 US$ 53.91 US$ 60,330,812 - 37.55 - 91.10
Last Trade Type Quantity Price Currency
18:58:51 30 US$ 53.41 USD

CRISPR Therapeutics (CRSP) Options Flow Summary

Overall Flow

Bullish

Net Premium

138k

Calls / Puts

300.00%

Buys / Sells

300.00%

OTM / ITM

100.00%

Sweeps Ratio

0.00%

CRISPR Therapeutics AG Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
4.31B 80.28M - 371.21M -153.61M -1.91 -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- - - -

more financials information »

CRISPR Therapeutics News

Date Time Source News Article
5/31/202415:15Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of..
5/31/202415:15Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of..
5/30/202415:26Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of..
5/29/202415:15Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of..
5/29/202407:00GlobeNewswire Inc.CRISPR Therapeutics to Participate in Upcoming Investor..
5/24/202415:15Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of..
5/23/202415:25Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of..
5/23/202407:14Edgar (US Regulatory)Form 8-K - Current report
5/23/202407:00GlobeNewswire Inc.CRISPR Therapeutics Strengthens Executive Leadership Team..
5/09/202407:30GlobeNewswire Inc.CRISPR Therapeutics to Present at the Bank of America..
5/08/202415:20Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]
5/08/202415:00GlobeNewswire Inc.CRISPR Therapeutics Provides Business Update and Reports..
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No CRSP Message Board. Create One! See More Posts on CRSP Message Board See More Message Board Posts

Historical CRSP Price Data

Period † Open High Low VWAP Avg. Daily Vol Change %
1 Week55.9056.499952.5254.40832,006-1.98-3.54%
1 Month56.7059.177451.0255.111,303,931-2.78-4.90%
3 Months79.5481.69551.0261.431,300,644-25.62-32.21%
6 Months70.4991.1051.0266.672,017,287-16.57-23.51%
1 Year65.0091.1037.5561.501,723,336-11.08-17.05%
3 Years119.44169.6737.5569.471,497,518-65.52-54.86%
5 Years36.00220.2132.0080.301,361,73117.9249.78%

CRISPR Therapeutics Description

CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.